Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease
Yona LevitesiD, Eric B. DammeriD, Yong RaniD, Wangchen TseringiD, Duc M. DuongiD, Measho H. Abreha, Joshna Dharmendrabhai GadhaviiD, Kiara LoloiD, Jorge A. Trejo‐LopeziD, Jennifer Phillips, Andrea Iturbe, Aya Erquizi, Brenda D. MooreiD, Danny Ryu, Aditya NatuiD, Kristy D. Dillon, Jose Torrellas, Corey Moran, Thomas B. Ladd, Kazi Farhana AfroziD, Tariful IslamiD, Jaishree S. Jagirdar, Cory C. FunkiD, Max RobinsoniD, Srikant RangarajuiD, , Todd Eliot GoldeiD
Abstract
We report a highly significant correlation between human Alzheimers disease (AD) brain proteome changes and those in CRND8 APP695NL/F transgenic mice. Comparing protein changes observed in the CRND8 mice with co-expression networks derived from human Alzheimers disease (AD), reveals both conserved and divergent module changes. Many proteins in the most highly conserved module (M42, matrisome) accumulate in plaques, cerebrovascular amyloid (CAA), dystrophic neuronal processes, or a combination thereof. Overexpression of two M42 proteins, midkine (Mdk) and pleiotrophin (PTN), in CRND8 mice brains leads to increased accumulation of A{beta} in plaques and in blood vessels; further, recombinant MDK and PTN enhance A{beta} aggregation into amyloid structures. Multiple M42 proteins bind to fibrillar A{beta}42 and a non-human amyloid fibril in vitro. Supporting this binding data, MDK and PTN co-accumulate with transthyretin (TTR) amyloid in the heart. Notably, our findings establish that proteomic changes in modules observed in human AD brains define an A{beta} amyloid "responsome" that is well conserved from mouse models to humans. Further, distinct amyloid structures appear to serve as scaffolds, facilitating the co-accumulation of proteins with signaling functions, and this co-accumulation may contribute to downstream pathological sequalae. Overall, this contextualized understanding of proteomic changes and their interplay with amyloid deposition provides valuable insights into the complexity of AD pathogenesis and potential biomarkers and therapeutic targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 57
- FWCI
- 16.09
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimers disease like pathology
Jeffrey N. Savas, Yizhi Wang, … John R. Yates·Cell ReportsPeer-reviewed·Nov 1, 2017
- A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease
Annett Boeddrich, Christian Haenig, … Erich E. Wanker·Genome MedicinePeer-reviewed·Jul 19, 2023
- Human-mouse proteomics reveals the shared pathways in Alzheimer's disease and delayed protein turnover in the amyloidome
Jay M. Yarbro, Xian Han, … Junmin Peng·Nature CommunicationsPeer-reviewed·Feb 11, 2025
- Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Arun Upadhyay, Deepak Chhangani, … Jeffrey N. Savas·Molecular NeurodegenerationPeer-reviewed·Sep 14, 2023
- Midkine Attenuates Aβ Fibril Assembly and Amyloid Plaque Formation
Masihuz Zaman, Shu Yang, … Junmin Peng·bioRxiv·Mar 20, 2025
- Network analysis of mouse brain proteomes resolves molecular and cellular endophenotypes of aging and Aβ pathology
Sruti Rayaprolu, Sneha Malepati, … Srikant Rangaraju·bioRxiv·Nov 6, 2026